Fig. 1: Oxidative stress in oxaliplatin resistant gastric cancer cells. | Cell Death & Disease

Fig. 1: Oxidative stress in oxaliplatin resistant gastric cancer cells.

From: Oxidative stress activates NORAD expression by H3K27ac and promotes oxaliplatin resistance in gastric cancer by enhancing autophagy flux via targeting the miR-433-3p

Fig. 1: Oxidative stress in oxaliplatin resistant gastric cancer cells.

A CCK-8 test for SGC-7901 to evaluate the IC50 after treating with or without NAC. Two way ANOVA test, NC vs NAC: 1 μg/ml L-OHP, t = 0.208, På 0.999; 2 μg/ml L-OHP, t = 2.914, p = 0.033, 4 μg/ml L-OHP, t = 1.249, P = 0.818; 8 μg/ml L-OHP, t = 3.642, P = 0.004; 16 μg/ml L-OHP, t = 0.936, P = 0.9521; 32 μg/ml L-OHP, t = 0.312, På 0.999; 64 μg/ml L-OHP, t = 1.041, P = 0.919. B CCK-8 test for SGC-7901-R to evaluate the IC50 after treating with or without NAC. Two way ANOVA test, NC vs NAC: 1 μg/ml L-OHP, t = 2.649, P = 0.068; 2 μg/ml L-OHP, t = 6.519, P < 0.000, 4 μg/ml L-OHP, t = 23.26, P < 0.000; 4 μg/ml L-OHP, t = 33.32, P < 0.000; 16 μg/ml L-OHP, t = 26.14, P < 0.000; 32 μg/ml L-OHP, t = 12.58, P < 0.000; 64 μg/ml L-OHP, t = 5.127, P < 0.000. C CCK-8 test for KATO III to evaluate the IC50 after treating with or without NAC. Two way ANOVA test, NC vs NAC: 1 μg/ml L-OHP, t = 1.998, P = 0.299; 2 μg/ml L-OHP, t = 9.172, P < 0.000, 4 μg/ml L-OHP, t = 1.816, P = 0.414; 8 μg/ml L-OHP, t = 1.544, P = 0.614; 16 μg/ml L-OHP, t = 0.817, P = 0.977; 32 μg/ml L-OHP, t = 0.999, P = 0.934; 64 μg/ml L-OHP, t = 0.545, P < 0.000. D CCK-8 test for KATO III-R to evaluate the IC50 after treating with or without NAC. Two way ANOVA test, NC vs NAC: 1 μg/ml L-OHP, t = 3.396, P = 0.008; 2 μg/ml L-OHP, t = 4.553, P < 0.000, 4 μg/ml L-OHP, t = 17.92, P < 0.000; 8 μg/ml L-OHP, t = 19.94, P < 0.000; 16 μg/ml L-OHP, t = 5.492, P < 0.000; 32 μg/ml L-OHP, t = 8.961, P < 0.000; 64 μg/ml L-OHP, t = 2.602, P = 0.077. E DHE method to test the ROS production in SGC-7901, SGC-7901-R, KATO III, and KATO III-R when treated with 0, 1, 1.5, 2.0, 2.5 μg/ml L-OHP. Tukey’s multiple comparisons test was used to evaluate the statistical significance of DHE treated with different concentration of L-OHP. SGC-7901, SGC-7901-R, KATO III, KATO III-R: 0 μg/ml vs 1 μg/ml, P < 0.000; 0 μg/ml vs 1.5 μg/ml, P < 0.000; 0 μg/ml vs 2.0 μg/ml, P < 0.000; 0 μg/ml vs 2.5 μg/ml, P < 0.000. F GSH expression in SGC-7901, SGC-7901-R, KATO III and KATO III-R when treated with 0, 1, 1.5, 2.0, 2.5 μg/ml L-OHP. Tukey’s multiple comparisons test was used to evaluate the statistical significance of GSH expression treated with different concentration of L-OHP. SGC-7901, SGC-7901-R, KATO III, KATO III-R: 0 μg/ml vs 1 μg/ml, P < 0.000; 0 μg/ml vs 1.5 μg/ml, P < 0.000; 0 μg/ml vs 2.0 μg/ml, P < 0.000; 0 μg/ml vs 2.5 μg/ml, P < 0.000. G SOD expression in SGC-7901, SGC-7901-R, KATO III, and KATO III-R when treated with 0, 1, 1.5, 2.0, 2.5 μg/ml L-OHP. Tukey’s multiple comparisons test was used to evaluate the statistical significance of SOD expression treated with different concentration of L-OHP. SGC-7901, SGC-7901-R, KATO III, KATO III-R: 0 μg/ml vs 1 μg/ml, P < 0.000; 0 μg/ml vs 1.5 μg/ml, P < 0.000; 0 μg/ml vs 2.0 μg/ml, P < 0.000; 0 μg/ml vs 2.5 μg/ml, P < 0.000. H MDA expression in SGC-7901, SGC-7901-R, KATO III, and KATO III-R when treated with 0, 1, 1.5, 2.0, 2.5 μg/ml L-OHP. Tukey’s multiple comparisons test was used to evaluate the statistical significance of MDA expression treated with different concentration of L-OHP. SGC-7901, SGC-7901-R, KATO III, KATO III-R: 0 μg/ml vs 1 μg/ml, P < 0.000; 0 μg/ml vs 1.5 μg/ml, P < 0.000; 0 μg/ml vs 2.0 μg/ml, P < 0.000; 0 μg/ml vs 2.5 μg/ml, P < 0.000.

Back to article page